Comparative role of tenofovir versus entecavir for treating patients with hepatitis B virus-related acute on chronic liver failure

• Published in: Journal of family medicine and primary care Vol. 10; no. 7; pp. 2642 - 2645
• Main Authors: Hossain, Sharker, Mahtab, Mamun, Das, Dulal, Noor-E-Alam, Sheikh, Mamun, Ayub, Khan, Md. Sakirul, Akbar, Sheikh, Rahman, Md, Rahman, Salimur
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01.07.2021; Medknow Publications and Media Pvt. Ltd; Wolters Kluwer - Medknow; Wolters Kluwer Medknow Publications
• Subjects: acute on chronic liver failure; Antiviral agents; Care and treatment; Comparative analysis; Diagnosis; Entecavir; hbv; Hepatitis B; Hepatitis B virus; Liver failure; Original; tenofovir; Bangladesh; entecavir; Acute on chronic liver failure; tenofovir; HBV
• ISSN: 2249-4863; 2278-7135
• DOI: 10.4103/jfmpc.jfmpc_2299_20

Introduction: The aim of the study was to compare the safety and efficacy of tenofovir versus entecavir for treatment of naive acute on chronic liver failure (ACLF) due to hepatitis B virus (HBV) (ACLF-B). Methods: Thirty-two patients aged 14-65 years were enrolled in the study. Diagnosis of ACLF was confirmed by clinical condition, biochemical analysis, and virological data. The causes of both chronic liver damages and acute insult in all patients were HBV. They were expressing HBV DNA in the sera, positive for IgM anti-HBc, had increased levels of serum bilirubin, compromised prothrombin time; and more than 50% patients had encephalopathy. The standard dose of tenofovir and entecavir was given. Results: The antiviral effects of tenofovir and entecavir were evident as most patients became negative for HBV DNA in the sera after 90 days of therapy. Also, the levels of serum bilirubin, CTP (Child-Turcotte-Pugh) and MELD (model for end-stage liver disease) score exhibited significant improvement due to antiviral therapy. Although the improvement of liver functions, and liver damages were detected in patients receiving both tenofovir and entecavir, the survival of the patients was significantly higher in those receiving tenofovir compared to entecavir-treated patients. Conclusion: This prospective study with limited number patients provides a challenge to assess the real potential of tenofovir over entecavir as therapeutic option for ACLF-B by conducting a multicenter clinical trial enrolling patient of different races and background.